23 Feb Cynata Therapeutics
Ross Macdonald, Ph.D., CEO
Oct. 13 | 9:15am | Oxford Biomedica Ballroom
Melbourne, Australia
(ASX: CYP)
In-person Presentation
Cynata Therapeutics is a clinical-stage stem cell and regenerative medicine company developing a therapeutic mesenchymal stem cell (MSC) platform technology, Cymerus™, utilizing induced pluripotent stem cells (iPSCs) as starting material. A successful clinical trial in GvHD has been completed, meeting all safety and efficacy endpoints. The company is undertaking a Phase III clinical trial in osteoarthritis with further clinical trials underway in respiratory distress and diabetic foot ulcers. A Phase II clinical trial in GvHD is expected to commence in late 2022 following IND clearance from the FDA. The Cymerus technology addresses a critical shortcoming in conventional methods of production of MSCs for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale. Cymerus utilizes a proprietary process that is independent of donor limitations providing an off-the-shelf production platform for therapeutic product manufacture.
